The relationship between serum levels of fibroblast growth factor 21 and diabetic retinopathy
Loading...
Date
2017-11-22
Journal Title
Journal ISSN
Volume Title
Publisher
Abstract
Fibroblast growth factor 21 (FGF21) is a major metabolic regulator that has been shown to be
elevated in a number of metabolic disturbances including type 2 diabetes mellitus (T2DM) and the
metabolic syndrome, but few studies about the relationship between serum FGF21 and the
complications of diabetes have been done. Since the association between FGF21 and diabetic
retinopathy is not clear, this study was conducted to investi- gate this relationship. In this
cross-sectional study, 61 subjects (14 healthy controls, 22 diabetic patients without retinopathy,
and 25 patients with diabetic retinopathy) were evaluated. All patients in the study were examined
for the presence of diabetic retinopathy. Various clinical and biochemical parameters including
FGF21 were evaluated and analyzed and compared between the study groups. Serum levels of FGF21
showed a significant difference between the three groups (P=0.003) but the difference between
diabetic patients with and without ret- inopathy was not significant (P=0.122). Regression model
was used to evaluate the role of FGF21 in predicting diabetic retinopathy. In the multivariate
logistic regression model after adjustment of systolic blood pressure and fasting blood glucose,
the level of FGF21 was not associated with diabetic retinopathy. In the multivariate mod- el, only
fasting blood glucose was associated with diabetic retinopathy (P=0.009). According to the results
of this study, serum levels of FGF21 in diabetic patients was higher than the control group but
these raised levels could not predict the presence of diabetic retinopathy.
Description
Table of contents
Keywords
Fibroblast growth factor 21, Type 2 diabetes mellitus, Diabetic retinopathy